Navigation Links
R-Tech Ueno Starts Early Phase II Clinical Trial for RK-023
Date:10/6/2009

TOKYO, Oct. 6 /PRNewswire/ -- R-Tech Ueno, Ltd. has started early Phase II clinical trial for RK-023, a physiologically active fatty acid derivative developed by the company -- a new compound targeted as a treatment for androgenetic alopecia (male pattern baldness) (Note 1).

Phase I clinical trial in healthy male volunteers that began in 2008 demonstrated the safety of RK-023 (Note 2). Early phase II clinical trial has been started for two purposes. One is to evaluate the safety of RK-023 for long-term use by men with pattern baldness. The other is to examine the preliminary effectiveness of this compound on hair growing. This clinical trial will be a double blind (Note 3), placebo-controlled (Note 4) study in which the study drug is applied to the scalp for 13 consecutive weeks.

"I am very pleased that early phase II clinical trial for RK-023 has started," said Dr. Yukihiko Mashima, president of R-Tech Ueno. "This is a compound that we are developing on our own for the treatment of male pattern baldness, which is part of our core dermatology operations. We plan to proceed with development activities quickly while conducting negotiations concerning alliances with companies in Japan and overseas."

R-Tech Ueno determines to complete the development of RK-023, quickly in order to provide assistance as soon as possible to men who are troubled by the loss of hair.

Notes:

  1. Androgenetic alopecia (male pattern baldness) is also called common baldness with aging. Following puberty, male hormones can prevent the regeneration of thick, long hair starting at the top of the skull and spreading forward. This hair is gradually replaced with thin, short hair. Eventually, this process leads to the atrophy of hair follicles and a decline in the number of strands of hair. Men first experience thinning of their hair and then baldness. This condition affects about 12 million men in Japan.
  2. See the R-Tech Ueno pres
    '/>"/>

SOURCE R-Tech Ueno, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023
2. R-Tech Ueno Completes Subject Enrollment in Phase 2 Clinical Study of 0.15% UF-021
3. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
4. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
5. Impliant Restarts Pivotal Clinical Trial for Patented TOPS(TM) Spine System
6. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
7. U.S. NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R)
8. Presbyterian Hospital Dallas Starts Advanced Breast-Cancer Risk-Assessment Program
9. Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND
10. Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
11. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014 PuraMed BioScience®, Inc., (OTC Pink: ... medicinal and healthcare products, announced it received the initial ... hemp-based, advanced headache relief product, for planned distribution to ... Colorado , Washington State , ... the MigraPure H Advanced headache relief gel formulation completed, ...
(Date:12/24/2014)... -- ResMed (NYSE: RMD ) today announced its ... device manufacturer BMC Medical Co., Ltd. The ... below infringe ResMed,s patents, and entered an order prohibiting BMC ... the United States : , iVolve nasal ... nasal pillows mask , iVolve full face mask ...
(Date:12/24/2014)... MASON, Ohio , Dec. 23, 2014 /PRNewswire/ ... industry-leading treatment decision support to healthcare providers for ... that it has secured $30 million in equity ... Virginia C. Drosos , President and Chief ... increased clinical adoption and development of Assurex Health,s ...
Breaking Medicine Technology:PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4
... SANTA CLARA, Calif., Aug. 15, 2011 NewCardio, Inc., (OTC ... results for the second quarter ended June 30, 2011. More ... Quarterly Report on Form 10-Q, filed today with the Securities ... QTinno® was selected by a top 5 global pharmaceutical company ...
... Aug. 15, 2011 Millennium HealthCare ... KBL, LLP, a Public Company Accounting Oversight Board (PCAOB) ... KBL, LLP provides a combination of ... emerging businesses. Their professionals maintain an entrepreneurial spirit and ...
Cached Medicine Technology:NewCardio Announces Financial Results for Its 2011 Second Quarter 2NewCardio Announces Financial Results for Its 2011 Second Quarter 3NewCardio Announces Financial Results for Its 2011 Second Quarter 4NewCardio Announces Financial Results for Its 2011 Second Quarter 5NewCardio Announces Financial Results for Its 2011 Second Quarter 6NewCardio Announces Financial Results for Its 2011 Second Quarter 7NewCardio Announces Financial Results for Its 2011 Second Quarter 8Millennium HealthCare Inc. Engages KBL, LLP 2
(Date:12/24/2014)... 2014 For chic ladies, new fashionable outfits ... part of their Holiday Wish List, Angeldress.co.uk has ... ways to accent ladies’ holiday wardrobe by launching a promotion ... all over the discount of 80% off, like a cheap ... ship. The company’s chic wedding dresses are among the hottest ...
(Date:12/24/2014)... 2014 The report offers details on ... various market dynamics such as the key trends, the ... wait time for U.S. sports medicine, the impact of ... the challenges faced by the market. , Browse report ... The report also provides an overview of the global ...
(Date:12/24/2014)... 24, 2014 Dental implants benefit millions ... tooth replacement. They offer the strongest and most secure ... other forms of tooth replacement. They will never slip ... adjacent teeth for support, and they prevent the jaw ... told that they are not suitable candidates for dental ...
(Date:12/24/2014)... Final Cut Pro X plugin ... Film Studios. , “The ProDenoise plugin that allows users to ... said Christina Austin, CEO of Pixel Film Studios. “ProDenoise is ... X editors toolbox.” , Final Cut Pro X users can ... footage with ProDenoise from Pixel Film Studios. ProDenoise can quickly ...
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, 2014 ... vaccine that U.S. officials are preparing to test in West ... vaccine produced a safe and potent immune response in Africans. ... more than 100 Ugandans in 2009 and 2010, prompted the ... protect a person against infection by Ebola, said study author ...
Breaking Medicine News(10 mins):Health News:Angeldress.co.uk Starts Its Big Sales by Offering Various Kinds of Cheap Clothes and Fashion Accessories 2Health News:Sports Medicine Market Report 2014: Global Industry Analysis, Share, Size, Trends, Growth and Forecast report 2Health News:Innovative Dental Implant Procedure to Gain Momentum in the New Year 2Health News:Pixel Film Studios released the ProDenoise plugin for Final Cut Pro X today. 2Health News:Early Study Offers Hope for an Ebola Vaccine 2Health News:Early Study Offers Hope for an Ebola Vaccine 3Health News:Early Study Offers Hope for an Ebola Vaccine 4
... new study shows exercise may allow for better brain ... mentally engaged.// ,Researchers from the Oregon Health and ... causes physical changes in the brain. Researchers say they ... want environmental factors such as smoking, drinking, and obesity ...
... new study shows a novel new drug is beneficial ... cells and is the first in a new class ... ,The drug is called cytotoxic T-lymphocyte-associated antigen 4-IgG1 or ... the treatment of rheumatoid arthritis. Researchers from Belgium conducted ...
... shows bone marrow stem cells may help restore damaged ... the American Heart //Association’s Scientific Sessions 2003 presented their ... that took place in 2001. Results from that trial ... his own bone marrow had improved heart function. ...
... say women will now have to talk seriously with their ... ,Pancreatic cancer affects only 31,000 Americans a year, but it ... study of 88,000 nurses found that those who took two ... had a 58 percent higher risk of pancreatic cancer.,Researchers expected ...
... A new study shows the symptoms women experience before ... the symptoms they expect to experience. ,Researchers interviewed ... and were discharged from five different medical sites. The ... asked the women to identify their symptoms before their ...
... new study shows children who are obese are more ... not overweight. ,Researchers from the University of Michigan studied ... The children and their parents took part in the ... weight, behavior, physical and mental health, education, demographic, and ...
Cached Medicine News:Health News:Aspirin usage linked with pancreatic cancer 2
... to match the pace and unique needs ... on Philips strong heritage in patient monitoring, ... has highly flexible screen configuration; an extensive ... such as Event Surveillance, EASI derived 12-lead ...
... is a comprehensive vital sign monitor. , ,Adult, ... products for efficiency in patient care., ,Standard Functions: ... - Temp - Multi-gas Sensor (HAL, ENF, ISO, ... ,Optional Functions: ,5-Lead ECG - FiO 2 - ...
... CS makes the outstanding ... CS even more flexible. ... Technologies, the Wireless Propaq ... ethernet Local Area Networks ...
... The Acuity Central Monitoring Station ... for up to 60 patients from ... interface uses simple point and click ... trackball. The clinician can initiate or ...
Medicine Products: